Orangello Indoor CBD Flower
Orangello Indoor 3 flowers
Bag of CBD Flowers
Orangello CBD analyzes

Orangello (Indoor) - CBD 14.1%

Citrus with tangy and sweet notes: Orangello is a 100% natural flower grown indoors in Switzerland. Hand-harvested, this Sativa-dominant hybrid has around 14% CBD and an intense aroma.
Regular price 15,80 € Sale price instead of 20,00 €

Availability: In stock – Ships within 24h

7,90 €/g
Tax included. Shipping calculated at checkout.
En Stock !
Livré en France sous 2 à 3 jours
Vous n'êtes pas en France ?

Summary

Orangello Indoor CBD Flower

  • Grown indoors in Switzerland (Indoor)
  • Flavours: Citrus, Tangy, Sweet
  • CBD 14%
  • Sativa-dominant hybrid
  • Hand-harvested

See all products:

Details

Orangello Indoor CBD Flower

Here is a 100% natural Orangello CBD Flower of Swiss origin, with a magnificent green colour and orange hues.

This is a flower with strong citrus scents, ranging from nectarine to blood orange depending on the phenotype. It is also very rich in CBD, with a level above 14%.

Superb aroma, very firm and compact buds, particularly careful trimming.

Cultivation method
Organic cultivation indoors in Switzerland (Indoor).

Species
Sativa-dominant hybrid.

Concentration

  • CBD: 14.16%
  • THC: 0.23%

Certification
Orangello Indoor CBD Flower grown in Switzerland, then certified by an independent, GMP-approved European laboratory.

Legislation
100% legal product in the European Union. This variety is a hybrid derived from varieties authorised in the European catalogue.

*Non-contractual photos, taken by us from the batch currently on sale*

Flavours

Orangello Indoor CBD Flower

  • Citrus
  • Tangy
  • Sweet

Similar products

Discover other Indoor CBD flowers:

Sources and references (4)

Official and scientific sources on the regulation, safety, composition and quality of this type of product. They are provided for information and are not health claims.

  1. MILDECA (2021). L'indispensable sur... le cannabidiol (CBD). MILDECA — drogues.gouv.fr. View the source
  2. MILDECA (2023). Le CBD. drogues.gouv.fr (Mission interministérielle de lutte contre les drogues et les conduites addictives). View the source
  3. Chevallier C, Charuel L, Richeval C, Chaouachi L, Del Valle L, Eiden C, Gaulier JM, Batisse A (CEIP-A Paris, Lyon, Montpellier ; CHU Lille) (2023). Cannabidiol : analyse de produits « CBD non pharmaceutiques » disponibles sur le marché en France. MILDECA — drogues.gouv.fr (rapport CEIP-A financé par la MILDECA). View the source
  4. Dryburgh LM, Bolan NS, Grof CPL, et al. (2018). Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. British Journal of Clinical Pharmacology. View the source

Recently viewed